Stay updated on Venetoclax Combo vs Azacitidine in AML Clinical Trial
Sign up to get notified when there's something new on the Venetoclax Combo vs Azacitidine in AML Clinical Trial page.

Latest updates to the Venetoclax Combo vs Azacitidine in AML Clinical Trial page
- Check2 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference0.6%
- Check9 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.1%
- Check16 days agoNo Change Detected
- Check30 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.3%
- Check37 days agoChange DetectedDifference0.3%
- Check45 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed information about a Phase 3 study of venetoclax in combination with azacitidine for treating Acute Myeloid Leukemia (AML), while adding references to collaborators and a revision number.SummaryDifference23%
- Check52 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.2%
Stay in the know with updates to Venetoclax Combo vs Azacitidine in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Venetoclax Combo vs Azacitidine in AML Clinical Trial page.